Carolina Partners in Mental HealthCare Expands Treatment Offerings to Include Revolutionary Mental Health Technology for Obsessive-Compulsive Disorder in North Carolina
NEWS PROVIDED BY Carolina Partners in Mental HealthCare, PLLC
May 13, 2019, 09:04 ET
RALEIGH, N.C., May 13, 2019 /PRNewswire/ — Carolina Partners, one of the most prominent mental and behavioral practices in the country, announced plans to offer patients access to BrainsWay‘s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for Obsessive-Compulsive Disorder (OCD). It will be one of the first practices in the area to provide Deep TMS for OCD, following its success in using Deep TMS to treat patients with depression. Carolina Partners currently utilizes Deep TMS for its patients throughout the Triangle region and will be expanding the program in the months to come.
“With the rise of public awareness around behavioral disorders and treatments, our patients are looking for new and innovative ways to manage symptoms and get back to their lives,” said Sandeep Vaishnavi, MD, PhD, TMS Medical Director at Carolina Partners. “Carolina Partners is thrilled to be an early adopter of BrainsWay’s new OCD device in North Carolina, and we are looking forward to helping our patients achieve positive outcomes with the treatment. We have already implemented BrainsWay’s depression helmet with high levels of success, and we expect to experience similar results with the OCD treatment.” Jeff Williams, CEO at Carolina Partners stated that “We are committed to bringing new care options to our patients who suffer from OCD and we are thrilled to be an early adopter of BrainsWay’s new OCD device. We are looking forward to helping our patients overcome this often debilitating disease.”
Deep TMS administers magnetic waves through a cushioned helmet to specific deep structures of the brain that impact OCD at a frequency similar to magnetic resonance imaging (MRI). The treatment is non-invasive with no systemic side effects and requires no hospitalization or anesthesia, allowing patients to return to normal activities, such as driving, immediately following the session. BrainsWay received FDA clearance for Deep TMS targeting OCD and is the first non-invasive medical device approved to treat OCD.
Carolina Partners is one of the largest privately owned behavioral and mental health practices in the country, with offices throughout the state of North Carolina. This multifaceted practice provides numerous treatment options for its patients including pharmacotherapy, psychotherapy, and TMS, as well as the latest technologies to help more objectively assess neuropsychiatric disorders using technologies such as quantitative EEG and pharmacogenetic testing.
Anyone interested in Deep TMS can call Carolina Partners at 919-929-9610 and ask to speak to our TMS Program Director or visit our website at www.carolinapartners.com.
About Carolina Partners in Mental HealthCare
With nearly 200,000 patient encounters in 2018, Carolina Partners in Mental HealthCare (CPMH) is the largest outpatient mental and behavioral healthcare services provider in North Carolina. CPMH’s 140+ clinicians provide the complete spectrum of psychiatric and psychological therapeutic services to patients across 37 sites and accept all major commercial insurance plans. In addition to being an innovator in technology and treatment modalities, including a leading TMS program, CPMH is also a vital research development partner for clinical trials to the pharmaceutical industry. CPMH is also a preferred referral destination for WakeMed, UNC Hospitals, and numerous primary care providers throughout the geographies it serves.
BrainsWay Ltd./ BrainsWay USA (NASDAQ: BWAY), is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders. The medical system developed and manufactured by the company is based on a unique breakthrough technology called Deep TMS, which can reach significant depth and breadth of the brain and produce broad stimulation and functional modulation of targeted brain areas. In the U.S., the Company’s device has been FDA cleared for the treatment of major depressive disorder (MDD) since 2013 and is now FDA cleared (De-Novo) for the treatment of Obsessive-Compulsive Disorder (OCD). The Company’s systems have also received CE clearance and are sold worldwide for the treatment of various brain disorders.